<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reile Janssen</style></author><author><style face="normal" font="default" size="100%">Lize Cuypers</style></author><author><style face="normal" font="default" size="100%">Lies Laenen</style></author><author><style face="normal" font="default" size="100%">Els Keyaerts</style></author><author><style face="normal" font="default" size="100%">Kurt Beuselinck</style></author><author><style face="normal" font="default" size="100%">Sunita Janssenswillen</style></author><author><style face="normal" font="default" size="100%">Bram Slechten</style></author><author><style face="normal" font="default" size="100%">Jannes Bode</style></author><author><style face="normal" font="default" size="100%">Elke Wollants</style></author><author><style face="normal" font="default" size="100%">Kristel Van Laethem</style></author><author><style face="normal" font="default" size="100%">Annabel Rector</style></author><author><style face="normal" font="default" size="100%">Mandy Bloemen</style></author><author><style face="normal" font="default" size="100%">Anke Sijmons</style></author><author><style face="normal" font="default" size="100%">Nathalie de Schaetzen</style></author><author><style face="normal" font="default" size="100%">Arnaud Capron</style></author><author><style face="normal" font="default" size="100%">Kurt Van Baelen</style></author><author><style face="normal" font="default" size="100%">Thierry Pascal</style></author><author><style face="normal" font="default" size="100%">Céline Vermeiren</style></author><author><style face="normal" font="default" size="100%">Bureau, Fabrice</style></author><author><style face="normal" font="default" size="100%">Vandesompele, Jo</style></author><author><style face="normal" font="default" size="100%">Pieter De Smet</style></author><author><style face="normal" font="default" size="100%">Wouter Uten</style></author><author><style face="normal" font="default" size="100%">Hugues Malonne</style></author><author><style face="normal" font="default" size="100%">Pierre Kerkhofs</style></author><author><style face="normal" font="default" size="100%">Jo De Cock</style></author><author><style face="normal" font="default" size="100%">Veerle Matheeussen</style></author><author><style face="normal" font="default" size="100%">Bruno Verhasselt</style></author><author><style face="normal" font="default" size="100%">Gillet, Laurent</style></author><author><style face="normal" font="default" size="100%">Gautier Detry</style></author><author><style face="normal" font="default" size="100%">Bertrand Bearzatto</style></author><author><style face="normal" font="default" size="100%">Jonathan Degosserie</style></author><author><style face="normal" font="default" size="100%">Coralie Henin</style></author><author><style face="normal" font="default" size="100%">Gregor Pairoux</style></author><author><style face="normal" font="default" size="100%">Piet Maes</style></author><author><style face="normal" font="default" size="100%">Van Ranst, Marc</style></author><author><style face="normal" font="default" size="100%">Lagrou, Katrien</style></author><author><style face="normal" font="default" size="100%">Elisabeth Dequeker</style></author><author><style face="normal" font="default" size="100%">Emmanuel André</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">COVID-19 Genomics Belgium consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.</style></title><secondary-title><style face="normal" font="default" size="100%">Virol J</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical Laboratory Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Testing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Diagnostic Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Feb 10</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">21</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Since the onset of the coronavirus disease (COVID-19) pandemic in Belgium, UZ/KU Leuven has played a crucial role as the National Reference Centre (NRC) for respiratory pathogens, to be the first Belgian laboratory to develop and implement laboratory developed diagnostic assays for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and later to assess the quality of commercial kits. To meet the growing demand for decentralised testing, both clinical laboratories and government-supported high-throughput platforms were gradually deployed across Belgium. Consequently, the role of the NRC transitioned from a specialised testing laboratory to strengthening capacity and coordinating quality assurance. Here, we outline the measures taken by the NRC, the national public health institute Sciensano and the executing clinical laboratories to ensure effective quality management of molecular testing throughout the initial two years of the pandemic (March 2020 to March 2022).&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>